Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.
Open Access
- 1 June 2010
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 88 (6), 682-691
- https://doi.org/10.1139/y10-060
Abstract
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate activity and inhibition of hepatic uptake and efflux transporters in sandwich-cultured human hepatocytes. The 4 transporters studied were sodium-dependent taurocholate cotransporter (NTCP), organic anion transporter (OATP), bile salt export pump (BSEP), and multidrug resistance-associated protein 2 (MRP2). ERA transporter inhibition was examined using the substrates taurocholate (for NTCP and BSEP), [3H]estradiol-17β-d-glucuronide (for OATP), and [2-d-penicillamine, 5-d-penicillamine]enkephalin (for MRP2). ERA substrate activity was evaluated using probe inhibitors ritonavir (OATP and BSEP), bromosulfalein (OATP), erythromycin (P-glycoprotein), probenecid (MRP2 and OATP), and cyclosporin (NTCP). ERAs were tested at 2, 20, and 100 µmol·L–1 for inhibition and at 2 µmol·L–1 as substrates. OATP, NTCP, or BSEP transport activity was not reduced by ambrisentan or darusentan. Bosentan and sitaxsentan attenuated NTCP transport at higher concentrations. Only sitaxsentan decreased OATP transport (52%), and only bosentan reduced BSEP transport (78%). MRP2 transport activity was unaltered. OATP inhibitors decreased influx of all ERAs. Darusentan influx was least affected (84%–100% of control), whereas bosentan was most affected (32%–58% of control). NTCP did not contribute to influx of ERAs. Only bosentan and darusentan were shown as substrates for both BSEP and P-glycoprotein efflux. All ERAs tested were substrates for at least one hepatic transporter. Bosentan and sitaxsentan, but not ambrisentan and darusentan, inhibited human hepatic transporters, which provides a potential mechanism for the increased hepatotoxicity observed for these agents in the clinical setting.Keywords
This publication has 28 references indexed in Scilit:
- Endothelin receptor antagonists in pulmonary arterial hypertensionEuropean Respiratory Journal, 2008
- Medical Therapy for Pulmonary Arterial HypertensionChest, 2007
- NO CLINICALLY RELEVANT PHARMACOKINETIC INTERACTION BETWEEN AMBRISENTAN AND SILDENAFILChest, 2006
- Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist SitaxsentanJournal of the American College of Cardiology, 2006
- Ambrisentan Therapy for Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2005
- Sitaxsentan Therapy for Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactionsClinical Pharmacology & Therapeutics, 2001
- Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine AKidney International, 2000
- Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavirBritish Journal of Clinical Pharmacology, 1997